10	1	P	E
SEP	0	4	2002

Docket No.: PF-0456-2 DIV

Certificate of Mailing I hereby errify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope TRANFOLDERSED to: Commissioner for Patents, Application Processing Division, Washington, D.C. 20231 on ____ Debbie Ellis Printed: IN THE UNITED STATES PATENT AND TRADEMARK OFFICE In re Application of: Lal et al. RECEIVED Title: **HUMAN MEMBRANE RECYCLING PROTEINS** Serial No.: 09/841,805 Filing Date: April 24, 2001 SEP 0 6 2002 Examiner: To Be Assigned Group Art Unit: 1653 TECH CENTER 1600/2900 Commissioner for Patents **Application Processing Division** Washington, D.C. 20231 TRANSMITTAL FEE SHEET **COPY OF PAPERS** Sir: **ORIGINALLY FILED** Transmitted herewith are the following for the above-identified application: 1. Return Receipt Postcard; 2. Request for Status (1 pg.); 3. Copy of official Filing Receipt (2 pp.); and 4. Revocation and Power of Attorney (2 pp.). The fee has been calculated as shown below. No additional Fee is required. Please charge Deposit Account No. 09-0108 in the amount of: The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17, or credit overpayment to Deposit Account No. 09-0108. A duplicate copy of this sheet is enclosed. Respectfully submitted, INCYTE GENOMICS, INC. Date: 30 august 2002 Michelle M. Stempien Reg. No. 41,327 Direct Dial Telephone: (650) 843-7219

3160 Porter Drive

Palo Alto, California 94304 Phone: (650) 855-0555

Fax: (650) 845-4166

COPY OF PAPERS ORIGINALLY FILED

Docket No.: PF-0456-2 DIV

Certificate of Mailing

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

By: Printed:

RECEIVED

In re Application of:

Lal et al.

SEP 0 6 2002

Title:

HUMAN MEMBRANE RECYCLING PROTEINS

Serial No.:

09/841,805

Filing Date:

April 24, 2001TECH CENTER 1600/290(

Examiner:

To Be Assigned

Group Art Unit:

1653

Commissioner for Patents Application Processing Division Washington, D.C. 20231

REQUEST FOR STATUS

Sir:

The above-referenced patent application was filed on April 24, 2001. The official Filing Receipt, mailed October 30, 2001 (copy attached), indicates that serial number 09/841,805 was assigned to the above-referenced application. To date no action has been received from the U.S. Patent and Trademark Office. Applicants respectfully request the status of the above-referenced application.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. **09-0108**.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: 30 august 2002

Michelle M. Stempien


Reg. No. 41,327

Direct Dial Telephone: (650) 843-7219

3160 Porter Drive

Palo Alto, California 94304 Phone: (650) 855-0555

Fax: (650) 845-4166



Incyte Pharmaceuticals, inc

SEP 0 4 2002



COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231 www.uspto.gov

APPLICATION NUMBER FILING DATE **GRP ART UNIT** FIL FEE REC'D ATTY.DOCKET.NO DRAWINGS **TOT CLAIMS** IND CLAIMS PF-0456-2 1653 710 09/841,805 04/24/2001 12 18 1 DIV

CONFIRMATION NO. 7874

FILING RECEIPT

OC000000006997410°

INCYTE GENOMICS, INC. PATENT DEPARTMENT 3160 Porter Drive Palo Alto, CA 94304

Date Mailed: 10/30/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate). RECEIVED

SEP 0 6 2002

TECH CENTER 1600/2900

Applicant(s)

Preeti Lal, Santa Clara, CA; Purvi Shah, Sunnyvale, CA; Neil C. Corley, Mountain View, CA;

Assignment For Published Patent Application

Incyte Pharmaceuticals, Inc.;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A DIV OF 09/360,125 07/23/1999 PAT 6,235,715 WHICH IS A DIV OF 09/004,502 01/08/1998 PAT 5,962,263

COPY OF PAPERS **ORIGINALLY FILED**

Foreign Applications

If Required, Foreign Filing License Granted 10/30/2001

Projected Publication Date: 02/07/2002

Non-Publication Request: No

Early Publication Request: No

Title

Human membrane recycling proteins

Preliminary Class

)

514

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).